Posted by Michael Wonder on 09 Sep 2021
Eloxx Pharmaceuticals announces fast track designation for ELX-02 for the treatment of cystic fibrosis patients with nonsense mutations
9 September 2021 - Eloxx Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations.
ELX-02 is currently in Phase 2 clinical trials in cystic fibrosis patients affected by nonsense mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene for whom there are no effective disease modifying therapies.
